Manual small incision cataract surgery (MSICS) with posterior chamber intraocular lens versus extracapsular cataract extraction (ECCE) with posterior chamber intraocular lens for age-related cataract.

Manual small incision cataract surgery (MSICS) with posterior chamber intraocular lens versus extracapsular cataract extraction (ECCE) with posterior chamber intraocular lens for age-related cataract.

BACKGROUND
Age -related cataract is a clouding of the lens, which occurs as a result of lens protein denaturation. Age -related cataract remains the leading cause of blindness globally, except in the most advanced countries. A key question is what is the best way of eliminating the lens, especially in low-income settings.


OBJECTIVE
To compare two different techniques of elimination of the lens in cataract surgery: the user is operating a small incision (MSICS) and extracapsular cataract extraction (ECCE).


METHOD
We searched CENTRAL (which contains the Cochrane Eyes and Trials Vision Group Register) (2014, Issue 8), Ovid MEDLINE, Ovid MEDLINE in process and Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946-September 2014), EMBASE ( January 1980 until September 2014), Latin America and the Caribbean Health Sciences Literature database (LILACS) (January 1982 to September 2014), web of Science Conference Proceedings Citation Index, Science (CPCI-S), (January 1990 to September 2014), which metaRegister of Controlled Trials (mRCT) ), and the World Health Organization (WHO) International Clinical Trials Registry platform (ICTRP) . We do not use date or language restrictions in the electronic searches for trials. Last we are looking for an electronic database on 23 September 2014.


METHOD
We included randomized controlled trials (RCTs) only. Participants in the trials were people with age-related cataract. We included trials in which MSICS with posterior chamber intraocular lens (IOL) implant compared to ECCE with posterior chamber IOL implant.


METHOD
Data were collected independently by two authors. We aim to collect data on presenting visual acuity of 6/12 or better and best corrected visual acuity less than 6/60 in three months and one year after surgery. Other results included intraoperative complications, complications of long-term (one year or more after surgery), quality of life, and cost effectiveness. There is not enough data available from the trial and to conduct a meta-analysis.

 Manual small incision cataract surgery (MSICS) with posterior chamber intraocular lens versus extracapsular cataract extraction (ECCE) with posterior chamber intraocular lens for age-related cataract.
Manual small incision cataract surgery (MSICS) with posterior chamber intraocular lens versus extracapsular cataract extraction (ECCE) with posterior chamber intraocular lens for age-related cataract.


RESULTS
Three randomized trial allocate people with age-related cataract to MSICS or ECCE included in this review (n = 953 participants). Two trials conducted in India and one in Nepal. experimental methods, such as random allocation and allocation concealment, not clearly explained; only in one experiment was an attempt to conceal the outcome assessors. Three studies reported follow-up six to eight weeks after surgery. In two studies, a participant in the group MSICS achieved without the aid of visual acuity 6/12 or 6/18 or better than the ECCE group, but overall no more than 50% of people achieve a good functional vision in two studies.

10/806 (1.2%) of those enrolled in the two trials had poor outcomes after surgery (best corrected vision of less than 6/60) with no evidence of a difference in risk between the two techniques (risk ratio (RR) 1.58 , 95% confidence interval (CI) 0.45 to 5.55). Surgically induced astigmatism more common with ECCE procedure of MSICS in two trials that reported this outcome. In one study there more complications intra and post-surgery in MSICS group. One study reported that the cost of two similar procedures.

dsGreen for Real-Time PCR, 100×, 100 uL

11010 100 uL
EUR 59

Anti-NMDA NR2A Subunit (100 ul) antibody

STJ120155 100 µl
EUR 526

Anti-NMDA NR2B Subunit (100 ul) antibody

STJ120160 100 µl
EUR 526

AccuGreenâ„¢ Standard 2, 100 ng/uL

99838-T 1ML
EUR 93
Description: Minimum order quantity: 1 unit of 1ML

GFP Antibody, 10 uL

P601-10 NULL
EUR 0

Cyanine3 azide, 100 uL, 10 mM/DMSO

11030 10 mM/DMSO
EUR 108

Cyanine5 azide, 100 uL, 10 mM/DMSO

13030 100 µl
EUR 108

Cyanine5.5 azide, 100 uL, 10 mM/DMSO

14030 100 µl
EUR 108

Cyanine7 azide, 100 uL, 10 mM/DMSO

15030 100 µl
EUR 108

Cyanine7.5 azide, 100 uL, 10 mM/DMSO

16030 100 µl
EUR 108

Cyanine3.5 azide, 100 uL, 10 mM/DMSO

12030 100 µl
EUR 108

TruStrip Sample Transfer Strips, 100-ul, 50/Pk (without sample tracking dye)

STS-100-50 1 Pk Ask for price

TruStrip Sample Transfer Strips, 100-ul, 50/Pk (with sample tracking dye)

STSD-100-50 1 Pk Ask for price

GFP Expressing Human Glioblastoma Cells

TR01-GFP 500,000 Cells
EUR 1354

S-100 Antibody

3958-100
EUR 316

GFP Expressing Human Gastric Carcinoma N87 Cells

TR02-GFP 500,000 Cells
EUR 1354

GFP Expressing Human Renal Adenocarcinoma Cells (ACHN)

TR04-GFP 500,000 Cells
EUR 1354

ROX azide, 5- isomer, 100 uL, 10 mM/DMSO

11230 100 µl
EUR 108

FAM azide, 5-isomer, 100 uL, 10 mM/DMSO

14130 100 ul
EUR 75

R6G azide, 5-isomer, 100 uL, 10 mM/DMSO

14430 100 µl
EUR 108

FAM azide, 6-isomer, 100 uL, 10 mM/DMSO

15130 100 ul
EUR 75

TAMRA azide, 5-isomer, 100 uL, 10 mM/DMSO

17130 100 µl
EUR 108

GFP Expressing Human Prostate Carcinoma Cells (DU 145)

TR03-GFP 500,000 Cells
EUR 1354

CD1b(100-1A5) Antibody

BNUB1044-100 100uL
EUR 209
Description: Primary antibody against CD1b(100-1A5), Concentration: 0.2mg/mL

CD1b(100-1A5) Antibody

BNC551044-100 100uL
EUR 199
Description: Primary antibody against CD1b(100-1A5), CF555 conjugate, Concentration: 0.1mg/mL

CD1b(100-1A5) Antibody

BNC611044-100 100uL
EUR 199
Description: Primary antibody against CD1b(100-1A5), CF660R conjugate, Concentration: 0.1mg/mL

CD1b(100-1A5) Antibody

BNC471044-100 100uL
EUR 199
Description: Primary antibody against CD1b(100-1A5), CF647 conjugate, Concentration: 0.1mg/mL

CD1b(100-1A5) Antibody

BNC051044-100 100uL
EUR 199
Description: Primary antibody against CD1b(100-1A5), CF405M conjugate, Concentration: 0.1mg/mL

CD1b(100-1A5) Antibody

BNC401044-100 100uL
EUR 199
Description: Primary antibody against CD1b(100-1A5), CF640R conjugate, Concentration: 0.1mg/mL

CD1b(100-1A5) Antibody

BNC431044-100 100uL
EUR 199
Description: Primary antibody against CD1b(100-1A5), CF543 conjugate, Concentration: 0.1mg/mL

CD1b(100-1A5) Antibody

BNC041044-100 100uL
EUR 199
Description: Primary antibody against CD1b(100-1A5), CF405S conjugate, Concentration: 0.1mg/mL

CD1b(100-1A5) Antibody

BNC801044-100 100uL
EUR 199
Description: Primary antibody against CD1b(100-1A5), CF680 conjugate, Concentration: 0.1mg/mL

CD1b(100-1A5) Antibody

BNCAP1044-100 100uL
EUR 199
Description: Primary antibody against CD1b(100-1A5), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

CD1b(100-1A5) Antibody

BNCB1044-100 100uL
EUR 199
Description: Primary antibody against CD1b(100-1A5), Biotin conjugate, Concentration: 0.1mg/mL

CD1b(100-1A5) Antibody

BNCH1044-100 100uL
EUR 199
Description: Primary antibody against CD1b(100-1A5), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

CD1b(100-1A5) Antibody

BNC881044-100 100uL
EUR 199
Description: Primary antibody against CD1b(100-1A5), CF488A conjugate, Concentration: 0.1mg/mL

CD1b(100-1A5) Antibody

BNC941044-100 100uL
EUR 199
Description: Primary antibody against CD1b(100-1A5), CF594 conjugate, Concentration: 0.1mg/mL

CD1b(100-1A5) Antibody

BNC681044-100 100uL
EUR 199
Description: Primary antibody against CD1b(100-1A5), CF568 conjugate, Concentration: 0.1mg/mL

CD1b(100-1A5) Antibody

BNC701044-100 100uL
EUR 199
Description: Primary antibody against CD1b(100-1A5), CF770 conjugate, Concentration: 0.1mg/mL

CD1b(100-1A5) Antibody

BNC811044-100 100uL
EUR 199
Description: Primary antibody against CD1b(100-1A5), CF680R conjugate, Concentration: 0.1mg/mL

M-MLV Reverse Transcriptase, 200u/ul

M2410-100 10,000 units
EUR 151

Pico488 dsDNA quantification reagent, 200x solution in DMSO, 100 uL

12010 100 uL
EUR 59

LB-100

B4846-100 100 mg
EUR 860

AIM-100

A3148-100 100 mg
EUR 1859
Description: AIM-100 is a small inhibitor of Ack1 tyrosine kinase with IC50 value of 24 nM [1]. AIM-100 mimicked ATP and inhibited the activity of Ack1 significantly and specifically.

bcl-2(100/D5) Antibody

BNUB0045-100 100uL
EUR 209
Description: Primary antibody against bcl-2(100/D5), Concentration: 0.2mg/mL

bcl-2(100/D5) Antibody

BNC040045-100 100uL
EUR 199
Description: Primary antibody against bcl-2(100/D5), CF405S conjugate, Concentration: 0.1mg/mL

bcl-2(100/D5) Antibody

BNC610045-100 100uL
EUR 199
Description: Primary antibody against bcl-2(100/D5), CF660R conjugate, Concentration: 0.1mg/mL

bcl-2(100/D5) Antibody

BNC470045-100 100uL
EUR 199
Description: Primary antibody against bcl-2(100/D5), CF647 conjugate, Concentration: 0.1mg/mL

bcl-2(100/D5) Antibody

BNC550045-100 100uL
EUR 199
Description: Primary antibody against bcl-2(100/D5), CF555 conjugate, Concentration: 0.1mg/mL

bcl-2(100/D5) Antibody

BNC050045-100 100uL
EUR 199
Description: Primary antibody against bcl-2(100/D5), CF405M conjugate, Concentration: 0.1mg/mL

bcl-2(100/D5) Antibody

BNC400045-100 100uL
EUR 199
Description: Primary antibody against bcl-2(100/D5), CF640R conjugate, Concentration: 0.1mg/mL

bcl-2(100/D5) Antibody

BNC430045-100 100uL
EUR 199
Description: Primary antibody against bcl-2(100/D5), CF543 conjugate, Concentration: 0.1mg/mL

bcl-2(100/D5) Antibody

BNC800045-100 100uL
EUR 199
Description: Primary antibody against bcl-2(100/D5), CF680 conjugate, Concentration: 0.1mg/mL

bcl-2(100/D5) Antibody

BNC810045-100 100uL
EUR 199
Description: Primary antibody against bcl-2(100/D5), CF680R conjugate, Concentration: 0.1mg/mL

bcl-2(100/D5) Antibody

BNCAP0045-100 100uL
EUR 199
Description: Primary antibody against bcl-2(100/D5), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

bcl-2(100/D5) Antibody

BNCH0045-100 100uL
EUR 199
Description: Primary antibody against bcl-2(100/D5), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

bcl-2(100/D5) Antibody

BNC940045-100 100uL
EUR 199
Description: Primary antibody against bcl-2(100/D5), CF594 conjugate, Concentration: 0.1mg/mL

bcl-2(100/D5) Antibody

BNC700045-100 100uL
EUR 199
Description: Primary antibody against bcl-2(100/D5), CF770 conjugate, Concentration: 0.1mg/mL

bcl-2(100/D5) Antibody

BNCB0045-100 100uL
EUR 199
Description: Primary antibody against bcl-2(100/D5), Biotin conjugate, Concentration: 0.1mg/mL

bcl-2(100/D5) Antibody

BNC880045-100 100uL
EUR 199
Description: Primary antibody against bcl-2(100/D5), CF488A conjugate, Concentration: 0.1mg/mL

bcl-2(100/D5) Antibody

BNC680045-100 100uL
EUR 199
Description: Primary antibody against bcl-2(100/D5), CF568 conjugate, Concentration: 0.1mg/mL

Human IgG/RF-adsorbent (Adsorb 50 serum samples of 100 ul)

RFAD11-50 50 tests
EUR 164

Human IgG/RF-adsorbent (Adsorb 50 serum samples of 100 ul)

RFAD11-500 500 tests
EUR 529

MTBK_20640-100

AR02-P0011-100 100ug
EUR 1133

Etoposide (100 mM)

1043-100
EUR 153

hCRP FRET 100

CH1008-100 1 Kit
EUR 212

hCRP TRF 100

CHTR1008-100 1 Kit
EUR 239

hAlbumin FRET 100

AH1005-100 1 Kit
EUR 212

hAlbumin TRF 100

AHTR1005-100 1 Kit
EUR 239

hIgG TRF 100

HITR1011-100 1 Kit
EUR 239

hInsulin FRET 100

IH1010-100 1 Kit
EUR 212

hInsulin TRF 100

IHTR1010-100 1 Kit
EUR 239

rIgG FRET 100

RI1015-100 1 Kit
EUR 212

bcl-2(100/D5 + 124) Antibody

BNUB1234-100 100uL
EUR 209
Description: Primary antibody against bcl-2(100/D5 + 124), Concentration: 0.2mg/mL

bcl-2(100/D5 + 124) Antibody

BNC551234-100 100uL
EUR 199
Description: Primary antibody against bcl-2(100/D5 + 124), CF555 conjugate, Concentration: 0.1mg/mL

bcl-2(100/D5 + 124) Antibody

BNC611234-100 100uL
EUR 199
Description: Primary antibody against bcl-2(100/D5 + 124), CF660R conjugate, Concentration: 0.1mg/mL

bcl-2(100/D5 + 124) Antibody

BNC471234-100 100uL
EUR 199
Description: Primary antibody against bcl-2(100/D5 + 124), CF647 conjugate, Concentration: 0.1mg/mL

bcl-2(100/D5 + 124) Antibody

BNC051234-100 100uL
EUR 199
Description: Primary antibody against bcl-2(100/D5 + 124), CF405M conjugate, Concentration: 0.1mg/mL

bcl-2(100/D5 + 124) Antibody

BNC401234-100 100uL
EUR 199
Description: Primary antibody against bcl-2(100/D5 + 124), CF640R conjugate, Concentration: 0.1mg/mL

bcl-2(100/D5 + 124) Antibody

BNC431234-100 100uL
EUR 199
Description: Primary antibody against bcl-2(100/D5 + 124), CF543 conjugate, Concentration: 0.1mg/mL

bcl-2(100/D5 + 124) Antibody

BNC041234-100 100uL
EUR 199
Description: Primary antibody against bcl-2(100/D5 + 124), CF405S conjugate, Concentration: 0.1mg/mL

bcl-2(100/D5 + 124) Antibody

BNC801234-100 100uL
EUR 199
Description: Primary antibody against bcl-2(100/D5 + 124), CF680 conjugate, Concentration: 0.1mg/mL

bcl-2(100/D5 + 124) Antibody

BNCB1234-100 100uL
EUR 199
Description: Primary antibody against bcl-2(100/D5 + 124), Biotin conjugate, Concentration: 0.1mg/mL

bcl-2(100/D5 + 124) Antibody

BNCH1234-100 100uL
EUR 199
Description: Primary antibody against bcl-2(100/D5 + 124), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

bcl-2(100/D5 + 124) Antibody

BNC881234-100 100uL
EUR 199
Description: Primary antibody against bcl-2(100/D5 + 124), CF488A conjugate, Concentration: 0.1mg/mL

bcl-2(100/D5 + 124) Antibody

BNC941234-100 100uL
EUR 199
Description: Primary antibody against bcl-2(100/D5 + 124), CF594 conjugate, Concentration: 0.1mg/mL

bcl-2(100/D5 + 124) Antibody

BNC681234-100 100uL
EUR 199
Description: Primary antibody against bcl-2(100/D5 + 124), CF568 conjugate, Concentration: 0.1mg/mL

bcl-2(100/D5 + 124) Antibody

BNC701234-100 100uL
EUR 199
Description: Primary antibody against bcl-2(100/D5 + 124), CF770 conjugate, Concentration: 0.1mg/mL

bcl-2(100/D5 + 124) Antibody

BNCAP1234-100 100uL
EUR 199
Description: Primary antibody against bcl-2(100/D5 + 124), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

bcl-2(100/D5 + 124) Antibody

BNC811234-100 100uL
EUR 199
Description: Primary antibody against bcl-2(100/D5 + 124), CF680R conjugate, Concentration: 0.1mg/mL

Taq DNA Polymerase, Ultra Pure, 5 units/ul

T2016-100 100,000 units
EUR 2885

PBS Tablets (100 ml)

2865-100
EUR 164

ATP Solution (100 mM)

2121-100
EUR 126

FUNNEL, 100 MM, PP

6120P-100 12/pk
EUR 47
Description: Reusable Plastics; Reusable Funnels

Mouse IgM FRET 100

IM1009-100 1 Kit
EUR 212

Mouse IgG FRET 100

MIG1012-100 1 Kit
EUR 212

100 BlotBot Reagent Reservoirs

RRVR-100 100pack
EUR 177
Description: BlotBot reagent reservoirs will allow dispensing of unique reagents during processing. Pack of 100.


CONCLUSION
No other studies from other countries besides India and Nepal and there are insufficient data cost-effectiveness of each procedure. Better evidence is needed before any changes can be implemented. Future studies should have a long-term follow-up and conducted to minimize bias revealed in this review with a larger sample size to allow inspection of its side effects.

Benoit

Related Posts

Polarly localized EccE1 is required for ESX-1 function and stabilization of ESX-1 membrane proteins in Mycobacterium tuberculosis.

Polarly localized EccE1 is required for ESX-1 function and stabilization of ESX-1 membrane proteins in Mycobacterium tuberculosis.

[Efficacy of double-incision extracapsular cataract extraction in the treatment of hard-nucleus cataract with low corneal endothelial cell density].

[Efficacy of double-incision extracapsular cataract extraction in the treatment of hard-nucleus cataract with low corneal endothelial cell density].

Comparison of outcomes following combined ECCE-trabeculectomy versus phacoemulsification-trabeculectomy.

Comparison of outcomes following combined ECCE-trabeculectomy versus phacoemulsification-trabeculectomy.

Phacoemulsification with posterior chamber intraocular lens versus extracapsular cataract extraction (ECCE) with posterior chamber intraocular lens for age-related cataract.

Phacoemulsification with posterior chamber intraocular lens versus extracapsular cataract extraction (ECCE) with posterior chamber intraocular lens for age-related cataract.

No Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Posts

January 2022
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  

Categories

Tags